Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

10.6K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
10.6K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

17.1K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
17.1K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.3K
Tumor Progression02:07

Tumor Progression

8.0K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
8.0K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.6K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type II alveolar epithelial cell-specific CAP1 loss is associated with spontaneous pulmonary fibrosis and altered complement 5 signaling.

BMC pulmonary medicine·2026
Same author

The role of laparoscopy in abdominal trauma: a comprehensive diagnostic and therapeutic approach.

Perioperative medicine (London, England)·2026
Same author

A Comprehensive Genomic Analysis of Nucleophosmin (NPM1) in Acute Myeloid Leukemia.

Cancers·2025
Same author

Higher diagnostic value of metagenomic next-generation sequencing in acute infection than chronic infection: a multicenter retrospective study.

Frontiers in microbiology·2024
Same author

Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment.

Mediators of inflammation·2023
Same author

Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB.

BMC infectious diseases·2023

Related Experiment Video

Updated: Apr 20, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.6K

Second primary malignancies in chronic myeloid leukemia.

Binay Kumar Shah1, Krishna Bilas Ghimire2

  • 1Cancer Center and Blood Institute, St. Joseph Regional Medical Center, 1250 Idaho Street, Lewiston, ID 83501 USA.

Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
|December 2, 2014
PubMed
Summary

Chronic myeloid leukemia (CML) patients face a higher risk of developing second primary malignancies (SPMs). This risk increased significantly after the introduction of imatinib and other tyrosine kinase inhibitors.

Keywords:
CMLImatinibSEERSecond primary malignancies

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K
Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K

Related Experiment Videos

Last Updated: Apr 20, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.6K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K
Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K

Area of Science:

  • Oncology
  • Hematology
  • Cancer Epidemiology

Background:

  • Survival for chronic myeloid leukemia (CML) patients has improved due to tyrosine kinase inhibitors like imatinib.
  • Data on second primary malignancies (SPMs) in CML patients is limited.

Purpose of the Study:

  • To analyze and compare SPM rates in CML patients before and after the imatinib era.
  • To assess the overall risk of SPMs in CML patients compared to the general population.

Main Methods:

  • Utilized the Surveillance, Epidemiology, and End Results (SEER) database for patient data from 1992-2009.
  • Employed the SEER Multiple Primary-Standardized Incidence Ratio (SIR) method to calculate relative SPM risks.
  • Analyzed data from 8,511 adult CML patients, identifying 473 SPMs in 446 individuals.

Main Results:

  • CML patients exhibited a significantly higher SIR for SPMs (1.27, P < 0.05), indicating a 27% increased risk compared to the general population.
  • An absolute excess risk of 32.09 SPMs per 10,000 person-years was observed in CML patients.
  • The rate of SPMs across all cancer sites was significantly higher in the post-imatinib era (SIR 1.48) compared to the pre-imatinib era (SIR 1.06, P = 0.03).

Conclusions:

  • Chronic myeloid leukemia patients have an elevated risk of developing second primary malignancies.
  • The risk of SPMs in CML patients has significantly increased in the post-imatinib era, suggesting a potential link to newer therapies.